Overview
Compare compounds researched for arousal, reproductive-axis signaling, social bonding pathways, and hormone-adjacent performance.
4 of 46 published compounds
$80.00
Sexual Health & Libido
libido, sexual health, reproductive signaling, hormone support
Goal hub next step
Build a libido & hormone support research path.
Use the quiz before choosing a compound, vendor, or PDF so the route reflects your goal, risk tolerance, and monitoring comfort.
Best options to research first
Ranked by evidence first, then risk. A research starting point, not a clinical recommendation.
PT-141
FDA-approved melanocortin agonist (Vyleesi) for HSDD in premenopausal women. Prescription only.
subcutaneous
Designed for acute/as-needed effect within an hour; BP effects peak in hours post-dose.
€27.29
3 tracked
Oxytocin
Well-studied neuropeptide with extensive human research on social/emotional processing. Prescription product.
intranasal, intravenous
Acute effects studied within hours post-dose; mixed efficacy across conditions.
1 tracked
Kisspeptin
Upstream regulator of reproductive axis (GnRH/LH/FSH). FDA-flagged for compounding concerns.
intravenous, subcutaneous
Acute LH response within ~45 minutes; fertility endpoints context-specific.
0 tracked
Lower-risk options
Higher-risk options
FDA cites serious adverse events: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, priapism. Immunogenicity/impurity concerns.
Trusted vendors for libido and reproductive-axis research
These vendors currently carry compounds in this goal category. Hub is the trust layer; outbound clicks happen after comparison.
XL Peptides
3 relevant compounds in hub
testing reports on product page
third-party testing reports linked on product page
UK, Europe, and rest of world via vendor shipping options
affiliate: direct product page
Amino Club
2 relevant compounds in hub
product page COA viewer
third-party purity testing; product-level COA on page
US/ROW (verify current policy)
affiliate: public program
Ignite Peptides
2 relevant compounds in hub
COA with order / verify current product report
third-party testing and COA documentation claimed by vendor; verify product-specific report
U.S. domestic territories only
affiliate: direct product page
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.